The Serodia Myco II particle agglutination test, which the manufacturers claim exclusively detects IgM antibody, was compared with two IgM-specific tests, a p-capture ELISA, and indirect immunofluorescence for their ability to detect recent Mycoplasma pneumoniae infection. In general there was good agreement among the three tests, all three having similar sensitivity. One hundred and nine (78%) of serum samples gave concordant results in all three assays. Several sera gave positive particle agglutination titres, however, while being negative by the two other assays, and the Serodia Myco The p-capture ELISA was performed as previously described.5 Negative and positive control sera were selected as previously described' and allocated 0 arbitrary units and 100 u, respectively. The positive control serum was diluted in negative control serum to give dilutions containing 33, 10, 3 3, 1, 0-33 and 0-1 u. Sera with > 0 33 u of M pneumoniae-specific IgM were regarded as positive.
Mycoplasma pneumoniae infection is frequently associated with severe pulmonary and nonpulmonary disease in man. ' The p-capture ELISA was performed as previously described.5 Negative and positive control sera were selected as previously described' and allocated 0 arbitrary units and 100 u, respectively. The positive control serum was diluted in negative control serum to give dilutions containing 33, 10, 3 3, 1, 0-33 and 0-1 u. Sera with > 0 33 u of M pneumoniae-specific IgM were regarded as positive.
The indirect immunofluorescence antibody (IFAT) test was performed as previously described. 4 Twenty five microlitre drops of the unsensitised particle suspension were added to the 1 in 10 serum dilutions to give a final dilution of 1 in 20, and 25 p1 drops of the sensitised particle suspension were added to the remaining wells giving final dilutions of 1 in 40 to 1 in 20480. The plates were shaken for 30 seconds and then covered and left undisturbed on a level surface at room temperature for three hours (or overnight).
The test was initially calibrated using the control sera dilution series. A proportion (66°o) of the sera which were positive in the particle agglutination test, but negative in the two other tests, contained M pneumoniae specific IgA (table). It is conceivable that these patients may have experienced recent M pneumoniae infection, but as there was no correlation between M pneumoniae-specific IgA indirect immunofluorescence and particle agglutination antibody titres this seems unlikely. There was also no relation between particle agglutination positivity, IgM negativity and age of patient.
In conclusion, we feel that while the Serodia MycoII test is a useful screening assay (with very few false negative titres), for evidence of recent M pneumoniae infection, we, unlike the manufacturers, would be unhappy to consider it as a definitive test for the presence of M pneumoniae-specific IgM. It may be better than the complement fixation test, however, as an indicator of recent M pneumoniae infection, particularly in younger patients in whom M pneumoniae IgM is found more frequently. 
